What Changed in Medicare Coverage in 2026: Key Updates You Need to Know

Fact-checked by the MyFinancial101 editorial team

Medicare coverage 2026 marks a structural turning point, not just a routine annual update. For the first time, three major reforms from the Inflation Reduction Act (IRA) are operating simultaneously: federally negotiated drug prices on 10 Part D medications, a hard out-of-pocket cap on prescription spending, and the elimination of the catastrophic coverage gap known as the “donut hole.” At the same time, CMS announced the standard monthly Part B premium would rise to $202.90, a $17.90 increase from 2025.

The timing matters. Medicare Advantage is contracting at a historically unusual rate, with plan exits and benefit cuts hitting millions of enrollees this year. Stand-alone Part D plan options shrank from 464 to 360, and the MA plans that remain offer fewer extras than they did even two years ago. For beneficiaries on fixed incomes, these changes are not abstract policy shifts, they show up directly in pharmacy bills, monthly Social Security deductions, and hospital cost-sharing.

This guide is written for anyone enrolled in Medicare or about to become eligible: current Part A and Part B beneficiaries, Medicare Advantage enrollees, Part D prescription drug plan holders, and caregivers managing coverage decisions for a family member. By the end, you will know exactly which costs changed, which drugs cost less, what to do if your MA plan was discontinued, and where the genuine opportunities for savings sit in 2026.

Step 1: How Much Did Medicare Part B and Part A Costs Increase in 2026?

The standard monthly Part B premium rose to $202.90 in 2026, and the annual Part B deductible climbed to $283, both meaningful increases that reduce your take-home Social Security payment or require a larger quarterly check. Most beneficiaries pay the standard rate; those with higher incomes pay more through Income-Related Monthly Adjustment Amounts (IRMAA).

The Exact Numbers

According to CMS’s official 2026 premium and deductible fact sheet, the Part B deductible increased by $26 from the 2025 level of $257. Once you satisfy that deductible, Medicare covers 80% of approved services and you owe the remaining 20% coinsurance, or your Medigap policy covers it if you have one.

Part A hospital costs also rose. The inpatient hospital deductible per benefit period is $1,736 in 2026, up $60 from $1,676 in 2025. Days 61 through 90 of a hospital stay now cost $434 per day, up from $419. Skilled nursing facility (SNF) coinsurance for days 21 through 100 increased to $217 per day from $209.50. The voluntary Part A premium for those without premium-free coverage rose to $565 per month.

What to Watch Out For

One honest concession: the Part B increase would have been roughly $29 per month, about $11 higher, had CMS not finalized a 90% spending reduction on certain skin substitute billing. This is a meaningful policy decision embedded in an actuarial calculation, and it illustrates that Medicare premiums are not purely driven by healthcare inflation. They also reflect coverage and billing policy decisions made throughout the year.

If your income crosses an IRMAA threshold, your Part B premium can be substantially higher than $202.90. IRMAA brackets adjust annually, so check your most recent tax return against the current thresholds on Medicare.gov’s 2026 fact sheet.

Step 2: What Does the $2,100 Part D Out-of-Pocket Cap Actually Mean for Your Pharmacy Bill?

The $2,100 annual out-of-pocket cap on Part D prescription drug spending is one of the most significant consumer-finance changes in Medicare’s history. Before 2024, there was no ceiling on what beneficiaries could owe for covered drugs, specialty drug patients could face five-figure annual costs with no protection. The cap changes that equation in a concrete way.

How the Cap Works in Practice

Once your total out-of-pocket drug costs, including your deductible, copays, and coinsurance, reach $2,100, covered formulary drugs cost you $0 for the rest of the calendar year. The cap resets on January 1. According to CMS’s Final CY 2026 Part D Redesign Program Instructions, the $2,100 figure represents a modest increase from the $2,000 cap introduced in 2025, reflecting an annual inflation adjustment built into the IRA’s design.

The maximum Part D deductible rose to $615 in 2026, up from $590. The base beneficiary premium is set at $38.99, though the average stand-alone Part D plan premium is projected to fall to roughly $34.50, down about $3.81 from 2025. That headline sounds positive, but it reflects a more complicated market shift discussed in Step 4.

The Prescription Payment Plan, which lets enrollees spread their out-of-pocket drug costs into monthly installments rather than paying in full at the pharmacy, auto-renews in 2026 unless you opt out. It does not reduce what you owe; it only smooths cash flow over 12 months. For someone on a tight fixed income, that distinction matters enormously when planning your annual budget.

What to Watch Out For

The cap only applies to drugs on your plan’s formulary. A drug your plan does not cover earns no protection under the $2,100 threshold, no matter how much you spend on it. Before assuming the cap protects you, verify that every medication you rely on appears in your specific 2026 formulary. Also note that drug plan premiums do not count toward the cap, only cost-sharing for covered drugs does.

Step 3: Which 10 Drugs Have Lower Prices Under Medicare’s Drug Negotiation Program?

Negotiated Maximum Fair Prices for the first 10 Medicare Part D drugs took effect January 1, 2026, and every Part D and Medicare Advantage drug plan is required to cover them at those negotiated rates. The drugs span several of the most common chronic conditions affecting older Americans.

The Drugs and the Savings

According to CMS’s negotiated drug price fact sheet, the 10 selected drugs include Eliquis (blood clots and atrial fibrillation), Jardiance (Type 2 diabetes and heart failure), Xarelto (blood clots), Januvia (Type 2 diabetes), and others treating cancer and autoimmune conditions. Out-of-pocket costs for these drugs are expected to fall roughly 50% on average for beneficiaries in stand-alone PDPs compared to 2025 costs. CMS projects $1.5 billion in total out-of-pocket savings for the approximately 9 million Part D enrollees who use these medications.

AARP analysis found that average out-of-pocket costs across 56 stand-alone PDPs would be under $100 per month for seven of the 10 negotiated drugs in 2026, compared to only two of the 10 in 2025. That shift is concrete and meaningful for patients who take these medications regularly.

The Honest Limitation

Savings vary widely depending on your specific plan and the formulary tier your plan assigns to each drug. Negotiated prices reduce what the plan pays the pharmacy, but your personal cost-sharing depends on which tier the drug occupies. A drug placed on a higher formulary tier, even at a negotiated price, may still cost more out of pocket than a generic alternative placed on a preferred tier. Check the Evidence of Coverage document for your specific plan to see the tier placement of any negotiated drug you take.

Fifteen additional drugs are currently being negotiated for 2026, with lower prices scheduled to take effect January 1, 2027. The negotiation program continues to expand annually under the IRA’s structure.

Step 4: What Happened to Medicare Advantage Plans in 2026 and What Should You Do?

Medicare Advantage is undergoing its most disruptive contraction in program history. The total number of individual Medicare Advantage plans available fell from 3,664 in 2025 to 3,329 in 2026, and approximately 2.9 million enrollees, roughly 10% of non-employer HMO and PPO plan members, received forced disenrollment notices because their plan exited the market. From 2018 through 2024, this rate averaged just over 1% annually. It jumped to 6.9% in 2025 and reached 10% in 2026.

Why Plans Are Leaving and What It Means Financially

The root cause is financial: MA insurers collectively reported $5.7 billion in underwriting losses in 2024. That pressure has pushed carriers to exit markets, cut extra benefits, and raise cost-sharing. The national median MA plan out-of-pocket maximum rose from $5,400 in 2025 to $5,900 in 2026, a 9.3% increase. The number of plans offering a Part B premium reduction dropped from 1,556 to 1,369., KFF reports approximately 35 million people enrolled in Medicare Advantage, a 3% increase year-over-year driven largely by Special Needs Plans (SNPs) rather than general HMO and PPO growth.

CMS also tightened what Special Supplemental Benefits for the Chronically Ill (SSBCI) can include starting in 2026, under the CY 2026 MA and Part D Final Rule. Cosmetic procedures, non-healthy food, alcohol, tobacco, and life insurance are now explicitly excluded. For enrollees who relied on food delivery benefits or non-health-related allowances, this is a genuine reduction in value.

The Medigap Guaranteed-Issue Right Almost No One Knows About

If your Medicare Advantage plan was discontinued and you are returning to Original Medicare, you have a guaranteed-issue right to purchase a Medigap (Medicare Supplement) policy without medical underwriting. This right exists for a limited window tied to your disenrollment date. Insurers cannot deny you coverage or charge you more based on health status during this period, even if you are outside your initial Medigap enrollment window and have pre-existing conditions.

This is one of the most financially significant protections in the Medicare system, and it is almost never mentioned in mainstream coverage of MA plan exits. If you received a disenrollment notice and are considering Original Medicare, exploring Medigap options immediately is worth your time.

Step 5: What Is the WISeR Prior Authorization Pilot and Does It Affect Original Medicare?

Starting January 1, 2026, a new prior authorization system called the WISeR model (Wasteful and Inappropriate Service Reduction) went live in Original Medicare, not Medicare Advantage, in six states: Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington. For the first time, traditional Medicare requires prior authorization or pre-payment review for 17 specific services in these states.

What Services Are Affected

The targeted services include skin substitutes, implanted electrical nerve stimulators, and arthroscopic knee surgery for osteoarthritis, among others. These represent fewer than 125 Part B billing codes, with CMS citing up to $5.8 billion in Medicare spending on unnecessary or inappropriate services in 2022 as justification for the model. According to KFF’s analysis of the WISeR pilot, the first-year impact is likely to be modest in scope, though the structural precedent is significant. The model is scheduled to run through December 31, 2031, and uses AI-assisted review to flag potentially wasteful claims.

WISeR does not change what Medicare covers. The underlying coverage rules remain the same. What changes is the procedural layer: providers in the six affected states must obtain pre-authorization for certain services before Medicare will pay. Administrative delays are a real risk for beneficiaries needing those procedures, even if the eventual coverage determination is favorable.

What to Watch Out For

The political situation around WISeR is genuinely uncertain. A House Appropriations amendment blocking funding for the model was adopted in September 2025, placing the program in legal and operational limbo even as CMS launched it in January 2026. If you live in one of the six states and your provider recommends one of the 17 affected services, ask specifically whether prior authorization has been obtained and what the expected timeline is. Do not assume the process will be as quick as a routine Medicare claim.

Step 6: How Does the New GLP-1 Weight-Loss Drug Coverage Work Under Medicare in 2026?

Starting July 1, 2026, CMS is launching the Medicare GLP-1 Bridge demonstration, a short-term pilot program giving eligible Part D beneficiaries access to certain GLP-1 drugs, including Ozempic and Mounjaro, for weight loss through December 31, 2027. This is a bridge program, not a permanent coverage decision, and the eligibility criteria are specific.

Who Qualifies and What It Costs

Eligibility requires meeting specific BMI thresholds and having at least one qualifying condition: heart failure, hypertension, chronic kidney disease, pre-diabetes, or a documented history of cardiovascular issues. The Bridge program operates entirely outside the normal Part D benefit structure, with a flat $50 copay collected at the pharmacy.

Here is the financial detail that almost no coverage of this program mentions: spending on Bridge GLP-1 drugs does not count toward the $2,100 Part D annual out-of-pocket cap. If you expect GLP-1 costs to be your primary drug expense and you are counting on the cap to limit your total spending, you will not receive that protection for these medications in 2026. According to Medicare.gov’s 2026 fact sheet, the Bridge program is designed as a transition to the forthcoming BALANCE model launching in 2027.

What to Watch Out For

GLP-1 drugs prescribed for diabetes, not obesity, have a separate coverage pathway through Part D and may already be covered under your formulary. If you currently take a GLP-1 for diabetes management, your existing Part D coverage applies and those costs do count toward your out-of-pocket cap. The Bridge program is specifically for weight management in eligible individuals without a qualifying diabetes diagnosis. Confirm with your plan and prescriber which pathway applies to your situation before assuming either pathway’s cost structure.

Step 7: Your 2026 Medicare Action Checklist, Five Steps to Protect Your Finances

The changes in 2026 require active decisions, not passive acceptance. The five actions below address the highest-value financial opportunities and the most consequential risks created by this year’s changes.

Action 1: Verify Your Drug Formulary Before Assuming You Are Protected

The $2,100 Part D cap only protects spending on drugs your plan covers. Log into your plan’s website or call the member services number on your card and confirm that every medication you take appears on the 2026 formulary. Pay specific attention to the tier placement of any of the 10 newly negotiated drugs, tier affects your copay even when the underlying negotiated price is lower. If a drug you need is not covered, this is the moment to explore a formulary exception request or a plan switch during a valid enrollment period.

Action 2: If Your MA Plan Was Discontinued, Act on Your Enrollment Period Immediately

A forced disenrollment from a Medicare Advantage plan triggers a Special Enrollment Period (SEP) to switch plans. If you choose to return to Original Medicare during this SEP, you also gain a time-limited guaranteed-issue right to purchase a Medigap policy without medical underwriting. This window does not last indefinitely. Contact a licensed Medicare counselor or your State Health Insurance Assistance Program (SHIP) within 60 days of your disenrollment notice to understand your Medigap options.

Action 3: Check Whether You Qualify for Extra Help

Extra Help, also called the Low-Income Subsidy (LIS), caps generic drug costs at $5.10 per prescription and brand-name drugs at $12.65 per prescription in 2026 for those who qualify. Eligibility extends to individuals with income up to 150% of the federal poverty level. You can review the 2026 poverty guideline changes to see where your income falls. Apply through SSA.gov or your local Social Security office.

Action 4: Evaluate Whether Medicare Advantage Still Makes Financial Sense for You

With the median MA out-of-pocket maximum rising to $5,900, fewer plans offering Part B premium reductions, and SSBCI benefits shrinking, the financial case for Medicare Advantage is weaker for many enrollees than it was three years ago. Run the numbers honestly: add your plan’s monthly premium, estimate your likely annual cost-sharing based on your health history, and compare that to the cost of Original Medicare plus a Medigap policy. For people with significant ongoing medical needs, Original Medicare with a Medigap plan may now be more predictable and potentially cheaper over a full year.

Action 5: If You Live in a WISeR State, Talk to Your Provider About Pending Procedures

Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington residents enrolled in Original Medicare should review any pending or upcoming procedures with their physician. Ask specifically whether the service falls under WISeR’s 17 targeted categories and, if so, whether prior authorization has been initiated. Given the political uncertainty around WISeR funding, stay informed about whether the program’s requirements change mid-year.

Managing healthcare costs well is part of a broader financial picture. If Medicare costs are affecting your monthly budget, it may also be worth exploring free health screenings available this winter to address preventive care without additional out-of-pocket expense, and reviewing whether LIHEAP energy assistance can free up room in your monthly budget.

Frequently Asked Questions

Does the $2,100 Part D cap apply to all my prescriptions, including drugs bought outside my plan?

No, the $2,100 annual out-of-pocket cap only applies to drugs on your plan’s formulary that you purchase through covered pharmacies. Drugs your plan does not cover, purchases at non-network pharmacies without coverage, and GLP-1 Bridge program drugs all fall outside the cap. According to CMS’s Part D Redesign instructions, plan premiums also do not count toward the threshold, only your actual cost-sharing for covered formulary drugs.

My Medicare Advantage plan was discontinued. Can I get a Medigap plan even though I have health problems?

Yes. If your MA plan was discontinued, you qualify for a guaranteed-issue right to purchase a Medigap policy, meaning insurers cannot deny you or charge more based on your health status. This right applies for a limited window following your disenrollment, even if you are well past your initial Medicare enrollment period. Contact your State Health Insurance Assistance Program (SHIP) immediately, the window is typically 63 days from your coverage end date, and missing it means returning to medically underwritten Medigap options.

Which specific drugs are cheaper under Medicare’s negotiation program starting in 2026?

The 10 drugs with federally negotiated prices effective January 1, 2026 include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/NovoLog insulin formulations. These treat conditions including atrial fibrillation, Type 2 diabetes, heart failure, cancer, and autoimmune disease. According to CMS’s negotiated price fact sheet, all Part D and Medicare Advantage drug plans must cover these drugs at the negotiated Maximum Fair Price.

I take Ozempic for weight loss. Will Medicare cover it under the new GLP-1 program in 2026?

Coverage through the GLP-1 Bridge demonstration begins July 1, 2026 and requires meeting specific BMI thresholds plus at least one qualifying condition such as heart failure, hypertension, chronic kidney disease, pre-diabetes, or cardiovascular history. The copay is $50 per fill. Critically, Bridge GLP-1 drug spending does not count toward your $2,100 annual Part D out-of-pocket cap, per Medicare.gov. If you take a GLP-1 for diabetes management rather than obesity, a separate Part D coverage pathway may already apply.

Should I switch from Medicare Advantage to Original Medicare in 2026?

For many beneficiaries, the case for Original Medicare is stronger in 2026 than it has been in years. The median MA out-of-pocket maximum has risen to $5,900, extra benefits are shrinking, and plan exits are at record levels. Original Medicare covers any provider who accepts Medicare nationwide, which matters most for people with complex or ongoing health needs. The meaningful trade-off is that Original Medicare without a Medigap plan carries no annual cost ceiling for Part A or the 20% Part B coinsurance, which can be costly for heavy users. Run your numbers with your actual health history before deciding, and consult a SHIP counselor before making a permanent switch.

Does the WISeR prior authorization model affect me if I have a Medicare Advantage plan?

No. WISeR applies only to Original Medicare (traditional fee-for-service Medicare) in the six pilot states. Medicare Advantage plans already use prior authorization under their own plan rules, which are separate from WISeR. If you are in an MA plan in Arizona, New Jersey, Ohio, Oklahoma, Texas, or Washington, your prior authorization requirements are set by your plan, not the WISeR model. Confirm the current status of WISeR’s funding with your provider if you are in Original Medicare in one of these states, given the ongoing legislative uncertainty.

How much will I pay for Part B in 2026 if my income is higher than average?

The standard Part B premium is $202.90 per month, but higher-income beneficiaries pay more through IRMAA surcharges. IRMAA tiers are based on your modified adjusted gross income (MAGI) from two years prior, meaning your 2024 tax return determines your 2026 IRMAA bracket. At the highest income tier, Part B premiums can exceed $600 per month. If your income dropped significantly since your most recent tax return due to retirement or a major life event, you can appeal your IRMAA determination using Form SSA-44, available through the Social Security Administration.

What happens if I miss the deadline to enroll in a new Part D plan after my old one was discontinued?

If your Part D plan was discontinued and you do not enroll in a new plan during your Special Enrollment Period, CMS will typically auto-enroll you in a benchmark plan in your area. Benchmark plans are the lowest-cost options available, but they may not cover your specific medications at favorable tiers. You may also face a late enrollment penalty if there is a gap in creditable drug coverage. Act proactively during your SEP rather than relying on auto-enrollment to protect your pharmacy costs.

Can my 2026 Medicare plan deny coverage for a drug I was taking in 2025?

Yes. Each plan’s formulary can change annually, and a drug covered in 2025 may be removed from the 2026 formulary or moved to a higher cost-sharing tier. If a drug you were previously taking is no longer covered, you can request a formulary exception, file an appeal, or switch to a plan that covers the drug during a valid enrollment period. CMS requires plans to provide a transition supply of covered drugs when a formulary change affects current enrollees, typically 30 days for non-long-term-care enrollees, giving you time to resolve coverage through the appropriate channel.